IJSR - International Journal of Scientific Research

Ms. Sagunthala Panneerselvam; Dr. Elangovan Kannan; Dr. Samu Subramaniam; Dr. Udhaya Balasubramanian; Dr. Safi Naaz; Dr. Arshad Akeel; Dr.Bhaskar; Dr. Shyama Subramanian

Volume : VIII, Issue : VIII, August - 2019

LIPID PROFILE AND LIPOPROTEIN (a) LEVELS IN CoQ10 SUPPLEMENTED ATORVASTATIN TREATED HYPERLIPIDAEMIC MYALGIA PATIENTS

Ms. Sagunthala Panneerselvam, Dr. Elangovan Kannan, Dr. Samu Subramaniam, Dr. Udhaya Balasubramanian, Dr. Safi Naaz, Dr. Arshad Akeel, Dr. Bhaskar, Dr. Shyama Subramanian

Abstract :

Statins are the most efficient drugs for reducing plasma LDL–C level and generally well–tolerated and adverse effects can be reduced by co–administration of coenzyme Q10 (CoQ10). In this study, 200 healthy normal subjects were taken as controls and 200 hyperlipidaemia subjects. From hyperlipidaemia subjects, 100 were treated with 40 mgs atorvastatin, 60 were atorvastatin treated hyperlipidaemic myalgia patients, out of 100 atorvastatin treated; 50 patients were atorvastatin treated hyperlipidaemia without CoQ10 and 50 patients were with CoQ10 supplementation. From atorvastatin treated hyperlipidaemic myalgia patients, 30 patients were without CoQ10 supplementation and 30 patients were with CoQ10 supplementation. Serum lipid profile and Lp(a) levels were measured before and after four weeks of treatment and protective effects of Co–Q10 was assessed. The results showed that atorvastatin significantly decrease lipid parameters and Lp(a) levels. Lipid parameters and Lp(a) levels in Co–Q10 supplemented groups were significantly lower than only statins administered groups. Our study provided new evidence supporting beneficial effects of Co–Q10 on statin–induced myopathic patients